Hepatogastroenterology, Cairo University, Cairo, Egypt.
Eur J Gastroenterol Hepatol. 2021 Mar 1;33(3):309-311. doi: 10.1097/MEG.0000000000001808.
On 12 March 2020, the WHO declared that the coronavirus disease 2019 (COVID-19) constitutes a pandemic. Cases of liver damage or dysfunction (mainly characterized by moderately elevated serum aspartate aminotransferase levels) have been reported among patients with COVID-19. However, it is currently uncertain whether the COVID-19 related liver damage/dysfunction is due mainly to the viral infection by itself or other coexisting conditions, such as the use of potentially hepatotoxic medications and the coexistence of systemic inflammatory response, respiratory distress syndrome-induced hypoxia, and multiple organ dysfunction. Individuals at high risk for severe COVID-19 are typical of older age and/or present with comorbid conditions such as diabetes, cardiovascular disease, and hypertension. This is also the same profile for those at increased risk for unrecognized underlying liver disease, especially nonalcoholic fatty liver disease. This could make them more susceptible to liver injury from the virus, medications used in supportive management, or hypoxia. So the aim of this review was to illustrate the clinical implications of COVID-19 on the liver in healthy and diseased states as well as the implications of common liver disorders on the outcome of COVID-19.
2020 年 3 月 12 日，世界卫生组织宣布 2019 年冠状病毒病（COVID-19）构成大流行。在 COVID-19 患者中，已经报告了肝脏损伤或功能障碍的病例（主要表现为血清天门冬氨酸氨基转移酶水平中度升高）。然而，目前尚不确定 COVID-19 相关的肝损伤/功能障碍主要是由于病毒感染本身还是其他共存条件引起的，例如潜在的肝毒性药物的使用以及全身性炎症反应、呼吸窘迫综合征引起的缺氧和多器官功能障碍的共存。COVID-19 重症高危人群的典型特征是年龄较大和/或患有合并症，如糖尿病、心血管疾病和高血压。对于未被识别的潜在肝脏疾病（尤其是非酒精性脂肪性肝病）风险增加的人群，情况也是如此。这可能使他们更容易受到病毒、支持性治疗中使用的药物或缺氧引起的肝损伤。因此，本综述的目的是说明 COVID-19 在健康和患病状态下对肝脏的临床影响，以及常见肝脏疾病对 COVID-19 结局的影响。
